Drugs on the horizon for diabesity

被引：44

作者：

Bailey C.J. ^{[1
]}

机构：

[1] Diabetes Group, Department of Life and Health Sciences, Aston University, Birmingham B4 7ET, Aston Triangle

来源：

Current Diabetes Reports | 2005年 / 5卷 / 5期

关键词：

Metformin; Liraglutide; Exenatide; Rimonabant; Dipeptidyl Peptidase;

D O I：

10.1007/s11892-005-0093-1

中图分类号：

学科分类号：

摘要：

The coexistence of type 2 diabetes and obesity presents a complex therapeutic challenge. Future combination tablets may include agents to address diabetes and any accompanying cardiovascular risk factors. Injectable agents that improve glycemic control and facilitate weight loss have recently become available: the soluble amylin analogue pramlintide provides an adjunct to insulin therapy in type 1 and type 2 diabetes, and the incretin mimetic exenatide can enhance prandial insulin release in type 2 diabetes. Orally active inhibitors of the incretin-degrading enzyme dipeptidyl peptidase-IV, agonists of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ ("dual PPARs"), and the CBI cannabinoid receptor inhibitor rimonabant are advanced in clinical development. Many novel antidiabetic and antiobesity compounds are emerging in preclinical development. Copyright © 2005 by Current Science Inc.

引用

页码：353 / 359

页数：6

共 73 条

[1]

Shafrir E., Animal models for non-insulin-dependent diabetes, Diabetes Metab. Rev., 8, pp. 179-208, (1992)

[2]

Lazar M.A., How obesity causes diabetes: Not a tall tale, Science, 307, pp. 373-375, (2005)

[3]

Montague C.T., O'Rahilly S., The perils of portliness. Causes and consequences of visceral adiposity, Diabetes, 49, pp. 883-888, (2000)

[4]

Maggio C.A., Pi-Sunyer F.X., Obesity and type 2 diabetes, Endocrinol. Metab. Clin. North Am., 32, pp. 805-822, (2003)

[5]

Scheen A.J., Lefebvre P.J., Management of the obese diabetic patient, Diabetes Rev., 7, pp. 77-93, (1999)

[6]

Krentz A.J., Bailey C.J., Oral antidiabetic agents: Current role in type 2 diabetes mellitus, Drugs, 65, pp. 385-411, (2005)

[7]

Turner R.C., Cull C.A., Frighi V., Holman R.R., Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49), JAMA, 281, pp. 2005-2012, (1999)

[8]

Bailey C.J., Whence and whither the fixed-dose combination?, Diabetes Vasc. Dis. Res., 2, pp. 51-53, (2005)

[9]

Garber A.J., Larsen J., Schneider S.H., Et al., Simultaneous glyburide/metformin is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes, Diabetes Obes. Metab., 4, pp. 201-208, (2003)

[10]

Bailey C.J., Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones, Diabetes Obes. Metab., 7, pp. 650-667, (2005)

← 1 2 3 4 5 6 7 8 →